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ABSTRACT 
Background: Clinical Decision Support Software (CDSS) solutions can automatically identify 
drug interactions and thereby aim to improve drug safety. However, data on the comparative 
performance of different CDSS to detect and appropriately classify interactions in real-life 
prescription datasets is limited. 
Objective: The aim of this study was to compare the results from two different CDSS 
analyzing the pharmacotherapy of a large population of psychiatric inpatients for drug 
interactions. 
Methods: We performed mass analyses of cross-sectional patient-level prescriptions from 
84,625 psychiatric inpatients using two CDSS, MediQ and ID PHARMA CHECK. Interactions 
with the highest risk ratings and the most frequent ones were reclassified according to the 
Zurich Interaction System (ZHIAS), a multidimensional classification that incorporates the 
Operational Classification of Drug Interactions (ORCA) and served as a reference standard. 
Results: MediQ reported 6,133 unique interacting combinations responsible for 270,617 
alerts affecting 63,454 patients. ID PHARMA CHECK issued 5,400 interactions and 157,489 
alerts in 48,302 patients. Only 2,154 unique interactions were identified by both programs, 
but overlap increased with higher risk rating. MediQ reported high-risk interactions in 2.5% of 
all patients, compared to 5% according to ID PHARMA CHECK. The positive predictive value 
for unique major alerts to be (provisionally) contraindicated according to ORCA was higher 
for MediQ (0.63) than for either of the two ID PHARMA CHECK components (0.42 for 
hospINDEX and 0.30 for ID MACS). MediQ reported more interactions, and ID PHARMA 
CHECK tended to classify interactions into a higher risk class, but overall both programs 
identified a similar number of (provisionally) contraindicated interactions according to ORCA 
criteria. Both programs identified arrhythmia as the most frequent specific risk associated with 
interactions in psychiatric patients. 
Conclusions: CDSS can be used for mass-analysis of prescription data and thereby support 
quality management. However, in clinical practice CDSS impose an overwhelming alert 
burden on the prescriber, and prediction of clinical relevance remains a major challenge. Only 
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a small subset of yet to be determined alerts appears suitable for automated display in 
clinical routine. 
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INTRODUCTION 
For the prevention of adverse drug reactions (ADR) and their associated morbidity, mortality 
and costs, drug interactions are a target of particular interest.[1-3] Although only a variable 
fraction of ADR is related to interactions, most clinically relevant interactions are known and 
should therefore be avoidable given sufficient awareness at the time of drug prescription.[4, 
5] Consequently, a number of clinical decision support software (CDSS) systems that are 
able to identify concomitantly prescribed interacting drugs and alert the prescriber were 
developed in recent years. 
Such CDSS are promoted as valuable tools to achieve safer prescribing, but they are also 
subject to important limitations that undermine their acceptance and efficacy in clinical 
practice.[6-9] Typically, their design focuses on high sensitivity to detect interacting drugs.[10-
13] However, the unavoidable trade-off is that highly sensitive CDSS based on 
comprehensive interaction databases impose an overwhelming alert burden on the 
prescribing physician. This may lead to “alert fatigue”, meaning that CDSS-triggered alerts 
are indiscriminately given little attention or even completely disregarded.[5, 14-17] Therefore, 
the classification and subsequent selection of drug interactions according to their clinical 
relevance and management implications is a major challenge for CDSS. Furthermore, 
available CDSS show major differences in their system architecture, underlying knowledge 
databases and classification systems, and only few studies evaluated and compared different 
CDSS using real-life patient data.[13, 18-20] Therefore, two aspects of CDSS deserve 
particular attention: first, the development of classifications that focus on clinical relevance 
and management implications of drug interactions; second, the development of methods that 
allow an objective comparison of the performance of different CDSS using real-life data. 
 
In order to address these issues, we recently developed an extended multidimensional 
operational classification system, the Zurich Interaction System (ZHIAS). It builds on the 
widely recognized OpeRational ClassificAtion (ORCA) that focuses on clinical management 
and identification of interactions that require medical interventions or monitoring.[19, 21] 
ZHIAS extends ORCA by another three dimensions that contain information on mechanisms 
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of interaction, management options and expected adverse outcomes in the format of 
dichotomous variable. ZHIAS also specifically considers the need to include information on 
individual patients into alert algorithms. ZHIAS was successfully applied in studies that 
evaluated interactions identified by CDSS,[22-24] and in a small pilot study where we used 
ZHIAS also as a “silver standard” for the comparison of different CDSS.[25] 
 
Besides improving the specificity of CDSS through studies that use real-life patient data for 
an evaluation of their performance, such studies also allow an analysis of local safety 
problems and may therefore aid in the customized development of preventive measures 
according to specific local needs. The frequency of critical medication errors varies between 
different medical specialties and settings, and within that context psychiatric patients are a 
population of special interest.[26] Many new psychopharmacologic drugs have been 
introduced in recent years, and although some may have improved safety profiles, previous 
studies reported that drugs acting on the central nervous system are among those most 
frequently implicated in ADR.[1, 4] Ageing of the psychiatric population and associated 
polypharmacy may also contribute to higher incidence of critical drug interactions.[26, 27] 
Only few studies specifically addressed medication safety in psychiatry and the role of CDSS 
in improving it.[26, 28] In a previous study, we therefore evaluated the frequency and clinical 
relevance of drug interactions in a large population of psychiatric inpatients based on the 
CDSS MediQ.[24] The current study extends our previous work through the use of another 
CDSS in order to evaluate and compare for the first time the identification and grading of drug 
interactions by two CDSS in a large real-life prescription dataset. 
 
 
SUBJECTS AND METHODS 
 
Data source and study population 
AMSP (“Arzneimittelsicherheit in der Psychiatrie” = Drug Safety in Psychiatry) is an ongoing 
international multicenter drug safety program that has been collecting data on 
 12 
pharmacotherapy and ADR from psychiatric hospitals in a naturalistic setting since 1993. Its 
methods have been described in detail elsewhere.[29, 30] Briefly, AMSP collects drug 
prescriptions and adverse events from more than 80 hospitals in Germany, Switzerland, 
Austria, and for some time Belgium and Hungary. All participating hospitals survey psychiatric 
inpatients on two reference days per year. The drugs administered on these days are 
recorded along with the patients’ age, gender and leading psychiatric diagnoses. For the 
current study we used the cross-sectional prescription data from patients surveyed between 
1994 and 2008. 
 
Study design and data processing 
We conducted a retrospective analysis of drug interactions in the anonymized AMSP 
prescription dataset using the CDSS MediQ and ID PHARMA CHECK®. The ethics 
committee had approved the study with a waiver of authorization. 
Processing and recoding of the raw data for interaction analyses have been described in 
detail in our previous study.[24] The original AMSP dataset contained cross-sectional data of 
88,029 psychiatric inpatients with a total of 334,056 prescriptions. After exclusion of patients 
with unidentifiable prescriptions and expansion of multi-ingredient preparations into individual 
constituents, 84,625 patients with 361,112 prescriptions remained suitable for automated 
mass analysis with ID PHARMA CHECK. For mass analysis with MediQ we also had to 
exclude substances not comprised in the MediQ database, thus leaving 84,607 patients with 
359,207 prescriptions. The most highly graded (“major”) and most frequent drug interactions 
identified by the two CDSS were subsequently reclassified according to ZHIAS. Interactions 
resulting in decreased efficacy were also identified as such by both CDSS and further 
evaluated. 
 
CDSS for mass analysis of drug interactions  
 
MediQ 
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MediQ is a CDSS designed as a web-based stand-alone interaction analysis solution. Mass 
analysis with MediQ has been described in our previous studies.[22-24] Briefly, we developed 
a customized web-interface that allowed us to perform mass analysis and automated 
identification of drug interactions with MediQ. MediQ uses a four-level hierarchical severity 
classification system of interactions (Table 1). All interactions with the MediQ “high danger” 
grading were defined as “major” in the current study. 
 
ID PHARMA CHECK 
ID PHARMA CHECK® is a CDSS designed for integrated use with computerized physician 
order entry (CPOE) and clinical information systems. It has been described in our previous 
pilot study in a small population of neurological inpatients.[25] ID PHARMA CHECK uses 
several information sources to determine possible drug interactions. Because each source 
has its own classification system, it can display a multitude of various alerts, where each is 
assigned an ID PHARMA CHECK three-level color-coded risk grade and an optional free text 
comment. The underlying information sources are: 1) hospINDEX drug interaction database, 
which assigns interactions to one of 6 categories including risk assessment and management 
recommendations. 2) ID MACS® medical semantic network, which comprises two main 
mechanisms for drug interaction detection: a) a database that contains interactions between 
certain drug groups and assigns them to one of three risk categories; and b) an algorithm that 
automatically detects interactions between cytochrome P450 inhibitors or inducers and 
substrates, as well as QTc-prolonging drugs. Interactions are assigned to one of three color-
coded risk categories, depending on the type of interaction and the number of simultaneously 
interacting substances. In order to compare the ID PHARMA CHECK output with the one 
from MediQ, ID PHARMA CHECK warnings were grouped according to their color codes. 
The classification systems of ID PHARMA CHECK and the definition of “major” interactions 
for the comparative purposes of this study are presented in Table 1. 
 
ZHIAS reclassification of interactions identified by CDSS 
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We selected the following interactions for ZHIAS reclassification: all interactions that were 
identified by either MediQ or ID PHARMA CHECK and had received the highest rating of the 
respective programs (“major”), the top 25 most frequent alerts identified by each program, 
and all interacting drug pairs that were simultaneously identified by MediQ, hospINDEX and 
each of the two ID MACS components (n=166). Altogether this accounted for 648 unique 
interacting pairs. In addition, another 819 interactions detected in this patient dataset had 
previously been reclassified as part of our previous studies, and this information was also 
available for our analyses. 
ZHIAS is a four-dimensional drug interaction classification system that was developed during 
the conduct of our previous studies.[22-24] ZHIAS is primarily based on the well-established 
and documented five-level grading according to the Operational Classification of Drug 
Interactions (ORCA) criteria.[19, 31] Briefly, ORCA’s five operational levels are defined as 
follows: Grade 1 = “contraindicated combination”. The risk associated with the drug 
interaction always outweighs the benefit. Grade 2 = “provisionally contraindicated”. The 
combination should be avoided unless the interaction is desired or no alternative is available, 
monitoring may be necessary. Grade 3 = “conditional risk”. Monitoring or alternatives should 
be considered. Grade 4 = “minimal risk”. No special action is needed, unless additional risk 
factors are present. Grade 5 = “no interaction”. ZHIAS’s other three major dimensions use 
dichotomous variables that relate to patient management, interaction mechanisms and 
expected adverse effects (see also results, Table 4). An expert panel consisting of clinical 
pharmacologists, pharmacists, neurologists and psychiatrists discussed the ZHIAS 
classifications of identified interactions until common agreement was achieved. For our 
assessments we referred to original and secondary literature, including but not limited to 
Hansten and Horn’s Drug Interactions: analysis and management [31], Stockley’s Drug 
Interactions,[32] and the list of QTc-prolonging drugs maintained by the Arizona Center for 
Education and Research on Therapeutics (AzCERT).[33] 
 
Data analysis 
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Data analysis was primarily descriptive with presentation of results in text, tables and figures, 
and calculation of medians, means and proportions as appropriate. Correlation of drug 
interaction grading systems was assessed using Spearman’s non-parametric rank correlation 
coefficient. The positive predictive value for a unique major interaction identified in the given 
population by a CDSS was calculated as the proportion of interactions classified as ORCA 
level 1 or 2 among all unique major interactions detected by the respective CDSS. Data 
management and analyses were performed with STATA Version 11.2 for MacOS X (STATA 
corporation, College Station, TX, USA) and SPSS Version 19 for Windows (SPSS, Inc., 
Chicago, IL, USA). 
 
 
RESULTS 
Demographics, medical diagnoses and pharmacotherapy of the study population have been 
described in detail in our previous study.[24] Median age of the patients was 51 years (range 
9-108), nearly 55% were female, and schizophrenia (34.3%) and mood (affective) disorders 
(30.5%) were the leading primary diagnoses. Antipsychotics and antidepressants were the 
most frequently prescribed drug classes, followed by cardiovascular agents and sedatives / 
anxiolytics. Patients had a mean of 3.9 concomitant drugs (median = 3); 5% of all patients 
had concomitant prescriptions for 9 or more substances. 
 
Identification and classification of drug interactions by CDSS 
An overview of the interaction alerts generated by MediQ and ID PHARMA CHECK is 
presented in Table 2. MediQ generated a total of 270,617 drug interaction warnings that 
affected 63,454 patients, excluding additional comments. Only 2,305 interactions in 2,156 
patients (2.5%) were classified as “high danger”. ID PHARMA CHECK issued fewer alerts, 
i.e. 157,489 affecting 48,302 patients, but a two-fold higher proportion of patients (5,842 
interactions in 4,235 patients; 5.0%) had combinations classified as “red”. 
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Identification of unique interacting drug pairs in the study population and their overlap 
between MediQ and ID PHARMA CHECK are presented in Figure 1. Altogether both CDSS 
issued alerts relating to 9,379 unique interacting drug combinations. MediQ identified 6,133 
and ID PHARMA CHECK 5,400 unique interactions. Only 2,154 (23.0%) of those were 
identified by both programs. Among the 5,400 unique combinations identified by ID PHARMA 
CHECK, quantitative contributions from its underlying sources HospINDEX (3,310 
combinations) and ID MACS (3,169 combinations) were similar and showed only a moderate 
overlap (1,079; 20.0%). Further analysis of the 3,169 interactions contributed by ID MACS 
showed that its database component had identified 1,370 unique interacting pairs, of which 
370 overlapped with hospINDEX and 342 pairs were labeled “red” (contraindicated). The ID 
MACS algorithm component, responsible for detection of CYP450-mediated interactions and 
combinations of QTc-prolonging drugs identified another 2,350 potentially interacting 
combinations (756 overlapping with other sources within ID PHARMA CHECK): 1,217 were 
combinations of inhibitors or inducers and substrates of various CYP450 enzymes, 968 of 
QTc-prolonging drugs, and another 165 involved both of those mechanisms. 
 
Stratification of unique interacting drug pairs reported by hospINDEX and MediQ over the 
identifying source and severity grades assigned by each source is presented in Table 3. 
Looking at “major” interactions, MediQ classified 198 out of 6,133 (3.2%) interactions as “high 
danger”, and hospINDEX 210 out of 3,310 (6.3%) as “likely to or can cause serious 
consequences”. Overall, we observed only a moderate correlation of severity grading 
between MediQ and hospINDEX for those 1,559 interactions that were identified by both 
sources (Spearman’s rank correlation coefficient r=-0.43, p<0.001; negative r is due to the 
inverse grading conventions). However, the proportion of interactions missed by either 
hospINDEX or MediQ steadily decreased with increasing severity grades, i.e. from 94.1% to 
30.1% for hospINDEX, and from 83.7% to 25.3% for MediQ. In other words, the probability 
that both sources identified an interaction was higher if either program had classified the 
interaction to a higher severity grade; nevertheless, even for “major” interactions the overlap 
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was far from complete, i.e. only 72 interactions received a “major” rating from MediQ and 
hospINDEX. 
 
ZHIAS reclassification of interactions 
An analysis of all reclassified interactions showed that the ORCA classification, used as the 
core component of ZHIAS and a “silver standard” in this study, correlated more closely with 
MediQ danger rating than with hospINDEX rating (|r|= 0.72 vs. 0.41, p<0.001). Correlation 
between ORCA classification and ID MACS database was even lower (r=0.163). Accordingly, 
also the positive predictive value for unique major alerts to be (provisionally) contraindicated 
according to ORCA was higher for MediQ (0.63) than for either of the two ID PHARMA 
CHECK components (0.42 for hospINDEX and 0.30 for ID MACS). This means that 
compared to ID PHARMA CHECK a unique “major” risk alert from MediQ was more likely to 
be contraindicated or provisionally contraindicated according to ORCA. 
ZHIAS reclassification of all “major” unique interactions reported by MediQ and ID PHARMA 
CHECK is presented in Table 4. Also for this subset of “major” alerts only, MediQ rating 
displayed a closer correlation with ORCA, i.e. we assigned a higher proportion of “major” 
alerts from MediQ than from ID PHARMA CHECK to ORCA classes 1 or 2 (62.7% for MediQ 
vs. 42.4% for hospINDEX and 29.8% for ID MACS). The presented additional ZHIAS 
components provide further information on management, mechanisms and expected possible 
adverse events of those interactions. In most cases, a therapeutic alternative with a lower risk 
may be available, and/or intense monitoring may be an acceptable option. Pharmacodynamic 
mechanisms of interaction were more frequent than pharmacokinetic mechanisms, and 
sometimes both contributed simultaneously to an interaction. Depending on the identifying 
source between 38.9% and 60.2% of interactions cause increased drugs effects; and MediQ 
as well as both sources of ID PHARMA CHECK indicate that arrhythmias, mostly related to 
QTc prolongations, are the single most frequent expected ADR: within the studied population 
3,908 patients (4.6%) had an interacting prescription with an elevated risk of arrhythmia rated 
as ORCA 1 (n=52) or 2 (n=3,856). 
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Among 38 warnings classified as “major” by MediQ, hospINDEX and ID MACS, one 
combination was “contraindicated” according to ORCA, i.e. amiodarone and domperidone, 
affecting one patient. Twenty-eight were provisionally contraindicated after reclassification; of 
those, 15 were combinations of MAO inhibitors with serotonergic agents or carbamazepine 
and 13 combinations of QTc-prolonging antipsychotics with other QTc-prolonging agents. 
The remaining 9 combinations had a conditional risk according to ORCA. 
 
Among all drug interactions detected by MediQ and/or ID PHARMA CHECK and 
subsequently reclassified according to ZHIAS, 58 individual drug pairs were classified as 
contraindicated (ORCA 1), and 193 as provisionally contraindicated (ORCA 2). Tables 5 and 
6 present the top 15 most frequently occurring interactions in the study population for each of 
those categories, respectively. Contraindicated combinations not identified by ID PHARMA 
CHECK included those of mefenamic acid with ibuprofen or diclofenac, and that of lithium 
with rofecoxib. The first is a combination of two non-steroidal anti-inflammatory drugs, i.e. a 
therapeutic duplication, and was found in 13 patients. The second was found in 8 patients, 
and rofecoxib has meanwhile been withdrawn from the market due to its unfavorable 
cardiovascular safety profile. In turn, MediQ did not report the therapeutic duplication of 
celecoxib with ibuprofen, and the QTc-prolonging combination of fluvoxamine with 
thioridazone. Regarding provisionally contraindicated combinations not in ID PHARMA 
CHECK, the most prominent is the concomitant administration of two different 
benzodiazepines (11 unique pairs, found in 1,315 patients). It is followed by the combination 
of olanzapine with carbamazepine that was prescribed to 550 patients. Of note, in those two 
cases, as well as in the most frequent ORCA 1 combination (ginkgo biloba with 
antithrombotics or aspirin), ORCA classification is not necessarily driven by a high resulting 
risk, but rather by the consideration that these combinations are unjustified due to a lack of 
(additional) efficacy. Nevertheless, in the case of benzodiazepines different pharmacokinetic 
properties may sometimes justify their concomitant administration. 
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DISCUSSION 
The current study evaluated the performance of two CDSS using cross-sectional prescription 
data of psychiatric inpatients. Also previous studies compared drug interactions and their 
classification between various compendia and CDSS.[10-12, 18, 20, 34-39] However, only 
few studies used real-life prescription data for this purpose and therefore also considered the 
prevalence of potentially interacting prescriptions in the target population.[13, 25] This 
approach provides a different and more realistic picture of CDSS performance in clinical 
practice. Furthermore, the high efficiency of the applied automated mass analyses, first 
presented in our previous study in the same population and now extended to another 
CDSS,[24] enables us to conduct such studies in very large populations. 
 
MediQ generated 1.7 times more warnings for the studied population than ID PHARMA 
CHECK. This may indicate higher sensitivity, but high sensitivity for low-risk interactions also 
implies excessive alert burden that undermines the acceptance and therefore efficacy of 
CDSS in clinical practice.[14, 17] ID PHARMA CHECK generated 2.5 times more “major” 
interaction alerts than MediQ. At first glance this suggests high sensitivity particularly for high-
risk interactions. However, MediQ showed better correlation with ORCA severity ranking, and 
after ZHIAS reclassification the number of identified interactions classified as ORCA 1 or 2 
was similar for both programs. In a previous study with a much smaller population we were 
able to reclassify all identified interactions according to ZHIAS and were therefore able to 
formally calculate comparative sensitivity and positive predictive value against ZHIAS as a  
“silver standard”.[25] There, MediQ had a higher sensitivity to detect interactions classified as 
ORCA 1 or 2, but because the number of low-risk alerts was also higher, the positive 
predictive value with regard to presumably relevant ORCA class 1 or 2 interactions was 
similar between both programs. In contrast, the current study calculated the positive 
predictive value for major alerts only, and this was now higher for MediQ. Overall it appears 
that both programs are able to effectively identify high-risk interactions at the price of a very 
high alert burden. 
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The low overlap of identified interactions between the two programs is remarkable and 
unexpected, although it concerns mainly low-risk interactions of questionable relevance in 
clinical practice. In order to reduce the alert burden, one may select display of high-risk 
interactions only. However, we found only a moderate correlation between different risk 
classifications. Previous studies that compared different interaction classification systems 
also reported significant disagreements in the inclusion and severity rating of interactions,[12, 
18, 20] and none of the currently available classifications can be considered as a gold 
standard. ORCA may be one of the most management-oriented and widely accepted 
classifications and was therefore used as a “silver standard” in this study being the major 
component of ZHIAS, but it is also subject to interrater variability. Indeed, there were also 
some discrepancies with our assessments vs. those e.g. from Hansten and Horn’s ORCA 
classifications.[24, 31] Reasons for disagreements include the weighting of therapeutic 
alternatives and risks vs. benefits, patient-specific factors that play an important but difficult to 
standardize role for the risk of a potential interaction in individual patients, and risks due to 
interactions between more than two interacting drugs, e.g. “triple interactions”. 
Considering such multiple interactions, ID PHARMA CHECK’s ID MACS algorithm aims to 
reduce number of alerts and better quantify risks through recognition of multiple combinations 
when more than two concomitant drugs are substrates of the same enzyme or are associated 
with QTc interval prolongation. Instead of issuing several low danger warnings liable to be 
ignored, ID PHARMA CHECK produces one high-risk alert that is more likely to catch the 
prescriber’s attention. Indeed, the majority of interactions that received top ratings from 
MediQ, hospINDEX and ID MACS were combinations of MAO inhibitors with SSRI or other 
serotonergic agents, and concomitant use of QTc-prolonging antipsychotics with other QTc-
prolonging agents, and these also frequently occur as triple interactions in our real-life 
prescription data. The extended classification of interaction mechanisms and expected 
adverse effects used in ZHIAS has the potential to take the concept of multiple risk factors in 
individual patients even further through integration with other patient-specific information: for 
example, a combination with hypotension as a possible side effect might be assigned a 
higher priority if this symptom is already present in a given patient. 
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ID PHARMA CHECK, optimized for integration into clinical information systems (CIS), may 
also analyze prescription data together with the information about a patient’s diagnoses and 
other clinical information, and therefore direct a prescriber’s attention towards symptoms that 
are a possible ADR resulting from an interaction. This can support the identification of ADR 
as such. In addition ID PHARMA CHECK issues alerts relating to single substances and 
duplicate medications. One should note that those extra features of ID PHARMA CHECK are 
not reflected in our comparative quantitative analyses, but may be of additional benefit if ID 
PHARMA CHECK is fully integrated into a hospital’s clinical information system. 
 
Beyond a comparison of different CDSS, the innovative use of CDSS for mass analyses of 
real-life pharmacotherapy can also make important contributions to local quality 
management. Our study demonstrates, that CDSS can efficiently identify the most 
problematic and most frequently occurring interacting prescriptions in a population. This 
information can subsequently be used for locally customized preventive measures, and an 
evaluation of the subsequent impact of interventions on prescribing behavior. For example, 
both CDSS identified arrhythmias as the single most frequent expected ADR associated with 
interactions in this population of psychiatric patients. This potentially lethal risk as well as the 
frequently identified therapeutic duplications should urge clinicians to be vigilant and avoid 
such combinations if possible or implement monitoring as appropriate. 
 
Finally, we must also consider some limitations of our study. First, we cannot exclude that 
some interactions remained undetected even by both CDSS, and we were therefore not able 
to calculate the true sensitivity and specificity of the CDSS regarding their identification of 
drug interactions. We cannot formally quantify this limitation but only assume that the very 
large number of drug interactions identified by both programs, many of which were not even 
mentioned in standard full-size reference textbooks, and the increasing overlap in detection 
with higher severity, makes it unlikely that we missed a high number of high-risk interactions. 
Second, the large number of 9,379 identified unique interactions precluded their complete 
reclassification. It is therefore possible that we missed some interactions that we would have 
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classified into a clinically relevant ORCA risk class. However, we reclassified also those 
interactions with the highest prevalence in the study population and used classifications from 
previous studies; and our previous smaller studies where we reclassified all interactions 
identified by CDSS demonstrated that we would miss only a negligible proportion of 
combinations classified as ORCA 1 or 2 with the approach taken in the current study. [22, 23, 
25] 
Third, because ID MACS is not designed as a stand-alone source of drug interaction 
knowledge but rather as a supplement to the information provided by hospINDEX, a direct 
comparison of drug interaction detection and classification was carried out only between 
hospINDEX as part of ID PHARMA CHECK and MediQ, or full ID PHARMA CHECK output 
and MediQ, but not with ID MACS separately. Another reason for this is that the severity 
rating of some ID MACS alerts considers more than two simultaneously interacting 
substances, whereas a comparison with MediQ must be limited to an analysis of drug pairs. 
Finally, one must also keep in mind that the databases of the studied CDSS are constantly 
updated. 
 
 
CONCLUSIONS 
MediQ and ID PHARMA CHECK show major differences in their performance regarding 
identification and grading of interactions, as well as presentation of their results. MediQ 
reported more interactions, and ID PHARMA CHECK tended to classify interactions into a 
higher risk class, but overall both programs identified a similar number of interactions 
classified as high risk according to ORCA criteria. The applicability in clinical routine is limited 
by an overwhelming alert burden on the prescriber for both programs. Therefore, the 
prediction of clinical relevance remains a major challenge, which even improved 
classifications and integration of additional patient-specific information into alert algorithm will 
not be able to fully resolve. Consequently, prescribers may only accept the use of either 
system for the identification of drug interactions if those are offered as an on-demand option 
for screening purposes. Therefore, additional development of small subsets of alerts suitable 
 23 
for automated display in clinical routine has recently been proposed, and those can also be 
co-implemented in CDSS that are integrated into clinical information systems with electronic 
prescription.[13, 40] Last not least our study also demonstrated that CDSS could also be 
used for mass-analysis of prescription data and thereby play an important role in 
comprehensive local drug safety and quality management concepts. 
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TABLES AND FIGURE LEGENDS 
 
FIGURE LEGENDS 
 
Figure 1: Overlap between unique combinations identified by MediQ and either of the two 
major ID PHARMA CHECK information sources. 
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TABLES 
 
Table 1: Classification of drug interactions by the clinical decision support software (CDSS) 
solutions MediQ and ID PHARMA CHECK, and our definition of “major” interactions 
(highlighted in bold script) that were selected for ZHIAS reclassification in the current study. 
 
 
CDSS Classification of interactions 
MediQ 3 = “strong”, high danger of ADR 
2 = “clinically relevant’, average danger of ADR 
1 = “relevant in exceptional cases”, low danger of ADR 
0 = “no interaction” or favorable combination 
ID PHARMA 
CHECK 
hospINDEX database 
(originally features 6 
risk and management 
categories)  
Red = “likely to or can cause serious consequences” 
Orange = “monitoring or dose adjustment may be required” 
Yellow = “monitoring advised” 
Blue = “usually no action required” 
ID MACS database Red = “absolute contraindication”, “contraindication” 
Orange = “relative/conditional contraindication” 
Yellow = “use with caution” 
ID MACS algorithm for 
interactions via 
CYP450 enzymes and 
QTc prolongations 
Red = “substantially increased risk”  
Orange = “increased risk” 
Yellow = “slightly increased risk”  
 
ADR = adverse drug reaction; CYP450 = cytochrome P450 
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Table 2: Overview of the output of the drug interaction analyses by MediQ and ID PHARMA 
CHECK. 
 
 
CDSS Risk category Total alerts  Patients affected Alerts per patient 
  n n % mean max 
       
MediQ High to low 270,617 63,454 75.0 3.20 52 
 High to average 73,308 37,752 44.6 0.87 19 
  High only 2,305 2,156 2.5 0.03 4 
        
ID PHARMA 
CHECK 
Red to yellow 157,489 48,302 57.1 1.86 29 
Red to orange 86,242 38,292 45.2 1.02 20 
 Red only 5,842 4,235 5.0 0.07 9 
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Table 3: Simultaneous stratification of unique interacting drug pairs reported by hospINDEX 
and MediQ over the identifying source and severity grades assigned by each source. 
 
 
MediQ 
alerts  
hospINDEX alerts 
In MediQ Not in MediQ Total 
High 
danger 
Average 
danger 
Low 
danger Total   
      n %  
In 
hospINDEX  
Interaction likely to cause serious consequences 30 19 2 51 22 30.1 73 
Interaction can cause serious consequences 42 28 9 79 58 42.3 137 
Monitoring or dose adjustment required 72 512 266 850 860 50.3 1,710 
Monitoring or dose adjustment may be required 0 49 56 105 107 50.5 212 
Monitoring advised 4 162 305 471 656 58.2 1,127 
Usually no special precautions required 0 0 3 3 48 94.1 51 
 Total 148 770 641 1,559 1,751 53.0 3,310 
Not in 
hospINDEX 
n 50 1,239 3,285 4,574    
% 25.3 61.7 83.7 74.6    
Total  198 2,009 3,926 6,133    
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Table 4: Results of the reclassification of all highest-ranked (“major”) unique interactions 
identified by MediQ and each ID PHARMA CHECK source according to ZHIAS. 
 MediQ high danger 
hospINDEX  
serious consequences 
likely / possible 
ID MACS 
contraindication, 
substantially 
increased risk 
 n % n % n % 
       
Total unique combinations 198 100.0 210 100.0 309 100.0 
       
ORCA level       
  ORCA 1: Contraindicated 32 16.2 18 8.6 12 3.9 
  ORCA 2: Provisionally contraindicated 92 46.5 71 33.8 80 25.9 
  ORCA 3: Conditional risk 70 35.4 105 50.0 173 56.0 
  ORCA 4: Minimal risk 4 2.0 16 7.6 44 14.2 
       
Management       
  Desired, risk-benefit OK 38 19.2 34 16.2 93 30.1 
  Alternative available 155 78.3 136 64.8 136 44.0 
  Monitoring recommended 159 80.3 175 83.3 262 84.8 
       
Mechanism of interaction1       
  Pharmacokinetic 87 43.9 83 39.5 93 30.1 
  Pharmacodynamic 149 75.3 161 76.7 272 88.0 
       
Expected adverse effects associated with the 
interaction2      
  Drug effect increased 77 38.9 113 53.8 186 60.2 
  Drug effect decreased 21 10.6 29 13.8 18 5.8 
  CNS – sedation, respiratory depression 17 8.6 36 17.1 80 25.9 
  CNS – serotonin syndrome 42 21.2 38 18.1 53 17.2 
  CNS – extrapyramidal syndrome 8 4.0 21 10.0 21 7.1 
  CNS – seizures  11 5.6 12 5.7 5 1.6 
  CNS – other  38 19.2 32 15.2 70 22.7 
  Nephrotoxicity 1 0.5 0 0.0 1 0.3 
  Hepatotoxicity 1 0.5 0 0.0 0 0.0 
  QTc prolongation / Torsade de pointes 97 49.0 88 41.9 159 51.5 
  Arrhythmia 103 52.0 113 53.8 169 54.7 
  Thrombosis 1 0.5 9 4.3 0 0.0 
  Bleeding 0 0.0 3 1.4 2 0.6 
  Hypertension 17 8.6 14 6.7 25 8.1 
  Hypotension 18 9.1 38 18.1 33 10.7 
  Other cardiovascular effects 1 0.5 2 1.0 5 1.6 
  Hyperkalaemia 9 4.5 2 1.0 0 0.0 
  Hypokalaemia, hyponatremia 5 2.5 2 1.0 3 1.0 
  Metabolic and endocrine effects 3 1.5 5 2.4 13 4.3 
  Gastrointestinal toxicity 1 0.5 0 0.0 0 0.0 
  Blood glucose up 2 1.0 0 0.0 0 0.0 
  Blood glucose down 1 0.5 0 0.0 0 0.0 
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  Muscle toxicity 3 1.5 2 1.0 2 0.7 
  Bone marrow toxicity 3 1.5 7 3.4 11 3.6 
  Other 10 5.1 7 3.4 11 3.6 
 
1 PK and PD mechanisms can be involved concomitantly; combined total may therefore exceed 100% 
2 Categories are not mutually exclusive and may therefore overlap. 
CNS = central nervous system; ORCA = Operational Classification of Drug Interactions 
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TABLE 5: 15 most frequent ORCA level 1 (contraindicated) combinations.  
 
 
1 combination was also automatically flagged as an interaction between CYP inducer/inhibitor and substrate or a 
concomitant administration of two QTc-prolonging substances. 
AC = absolute contraindication; DA = dose adjustment; EPS = extrapyramidal symptoms; GI = gastrointestinal; 
ORCA = Operational Classification of Drug Interactions; RC = relative contraindication; SC = serious 
consequences; SSRI = selective serotonin reuptake inhibitor 
 
 
 
 Frequency in 84,625 patients Danger rating Expected 
adverse effects 
Drug combination n % MediQ hosp- INDEX 
ID 
MACS 
Ginkgo biloba and 
antithrombotics or aspirin 102 0.12 Average 
Monitoring / 
DA required - Bleeding 
Cisapride - tricyclic 
antidepressants 17 0.02 High - * QTc prolongation 
Mefenamic acid - 
ibuprofen, diclofenac 13 0.02 Average - - GI bleeding 
Celecoxib - ibuprofen 9 0.01 - - Caution GI bleeding 
Rofecoxib - lithium 8 0.01 High - - Lithium intoxication 
Amiodarone - digoxin 7 0.01 High Monitoring / DA required - 
Arrhythmia, digoxin 
toxicity 
Carbamazepine - 
clarithromycin 7 0.01 High 
May cause 
SC * 
Carbamazepine 
toxicity 
Carbamazepine -
midazolam 7 0.01 High 
Monitoring / 
DA required * 
Loss of midazolam 
efficacy 
Fluvoxamine - 
thioridazine 7 0.01 - 
Likely to 
cause SC AC
1 QTc prolongation 
Atazanavir - 
pantoprazole 6 0.01 Average 
Likely to 
cause SC - 
Loss of antiviral 
activity 
Fenoterol, salmeterol – 
nonselective β-blockers 6 0.01 High 
Monitoring 
/DA required - Bronchospasm 
Fentanyl - tramadol 5 0.01 Average - - Serotonin syndrome, seizures 
Haloperidol - 
erythromycin 5 0.01 High 
Monitoring / 
DA required RC
1 EPS, QTc prolongation 
Levodopa - tiapride 5 0.01 High May cause SC - 
Loss of levodopa 
efficacy 
Sibutramine - SSRI, 
other serotonergic drugs 5 0.01 Varies 
Likely to 
cause SC - Serotonin syndrome 
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TABLE 6: 15 most frequent ORCA level 2 (provisionally contraindicated) combinations.  
 
 
1 Combination was also automatically flagged as an interaction between CYP inducer/inhibitor and substrate or a 
concomitant administration of two QTc-prolonging substances. 
2 Some combinations were missing from MediQ 
AC = absolute contraindication; CNS = central nervous system; DA = dose adjustment; EPS = extrapyramidal 
symptoms; GI = gastrointestinal; MAO = monoamine oxidase; ORCA = Operational Classification of Drug 
Interactions; RC = relative contraindication; SC = serious consequences; SSRI = selective serotonin reuptake 
inhibitor 
 Frequency in 84,625 patients Danger rating Expected 
adverse effects 
Drug combination n % MediQ hosp- INDEX 
ID 
MACS 
Any two 
benzodiazepines 1,315 1.55 Average - - Sedation 
Haloperidol - clozapine 822 0.97 Average - RC1 QTc prolongation, sedation 
Haloperidol - olanzapine 687 0.81 Average - RC1 QTc prolongation, metabolic, CNS 
Haloperidol - 
carbamazepine 650 0.77 Average 
Monitoring 
advised 
1 Loss of haloperidol efficacy 
Haloperidol - 
levomepromazine 624 0.74 Average - Caution 
EPS, QTc 
prolongation 
Carbamazepine - 
olanzapine 550 0.65 Average - - 
Loss of olanzapine 
efficacy, metabolic 
Carbamazepine - 
risperidone 500 0.59 Average 
Monitoring 
advised - 
Loss of risperidone 
efficacy, other CNS 
Clozapine - fluvoxamine 402 0.48 High Monitoring / DA required 
1 Bone marrow toxicity 
Haloperidol - tricyclic 
antidepressants 232 0.27 Average 
Monitoring / 
DA required RC
1 QTc prolongation, seizures 
MAO inhibitors - tricyclic 
antidepressants 212 0.25 High
2 Monitoring / DA required AC Serotonin syndrome 
Lithium - 
hydrochlorothiazide 190 0.22 High 
Monitoring / 
DA required - Lithium intoxication 
Carbamazepine - 
clozapine 183 0.22 Average 
Likely to 
cause SC AC
1 Agranulocytosis 
Clozapine - olanzapine 177 0.21 High - 1 QTc prolongation, metabolic 
Clozapine - quetiapine 168 0.20 Average - 1 
QTc, bone marrow 
toxicity, 
hypotension, 
sedation 
